Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson consumer Health Segment Total [spun off as Kenvue in FY2023Q3] — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, Q2 2023
4,011
Period ended Jul 2, 2023
Change on a year earlier
+5.4%
3,805 in Q2 2022
History
30 quarters
Since Q1 2016
Sources
15
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Consumer Health Segment Total [spun off as Kenvue in FY2023Q3] — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2023 | Jul 2, 2023 | 4,011 | +5.4% | Form 10-Q (filed 2023-07-31) ↗ |
| Q1 2023 | Apr 2, 2023 | 3,852 | +7.4% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2022 | Jan 1, 2023 | 3,767 | +1.0% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2022 | Oct 2, 2022 | 3,795 | -0.4% | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2022 | Jul 3, 2022 | 3,805 | -1.3% | Form 10-Q (filed 2023-07-31) ↗ |
| Q1 2022 | Apr 3, 2022 | 3,586 | -1.5% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2021 | Jan 2, 2022 | 3,728 | -7.1% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2021 | Oct 3, 2021 | 3,812 | +8.5% | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2021 | Jul 4, 2021 | 3,854 | +16.9% | Form 10-Q (filed 2022-07-29) ↗ |
| Q1 2021 | Apr 4, 2021 | 3,641 | +0.4% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Jan 3, 2021 | 4,015 | +12.6% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2020 | Sep 27, 2020 | 3,514 | +1.3% | Form 10-Q (filed 2021-10-29) ↗ |
| Q2 2020 | Jun 28, 2020 | 3,296 | -7.0% | Form 10-Q (filed 2021-07-29) ↗ |
| Q1 2020 | Mar 29, 2020 | 3,625 | +9.3% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 29, 2019 | 3,567 | +0.9% | Form 10-K (filed 2020-02-18) ↗ |
| Q3 2019 | Sep 29, 2019 | 3,469 | +1.6% | Form 10-Q (filed 2020-10-23) ↗ |
| Q2 2019 | Jun 30, 2019 | 3,544 | +1.1% | Form 10-Q (filed 2020-07-24) ↗ |
| Q1 2019 | Mar 31, 2019 | 3,318 | -2.4% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 30, 2018 | 3,536 | -0.1% | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2018 | Sep 30, 2018 | 3,415 | +1.8% | Form 10-K (filed 2019-02-20) ↗ |
| Q2 2018 | Jul 1, 2018 | 3,504 | +0.7% | Form 10-K (filed 2019-02-20) ↗ |
| Q1 2018 | Apr 1, 2018 | 3,398 | +5.3% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 3,540 | +3.1% | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2017 | Oct 1, 2017 | 3,356 | +2.9% | Form 10-K (filed 2019-02-20) ↗ |
| Q2 2017 | Jul 2, 2017 | 3,478 | +1.7% | Form 10-K (filed 2019-02-20) ↗ |
| Q1 2017 | Apr 2, 2017 | 3,228 | +1.0% | Form 10-K (filed 2019-02-20) ↗ |
| Q4 2016 | Jan 1, 2017 | 3,432 | – | Form 10-K (filed 2018-02-21) ↗ |
| Q3 2016 | Oct 2, 2016 | 3,261 | – | Form 10-K (filed 2018-02-21) ↗ |
| Q2 2016 | Jul 3, 2016 | 3,419 | – | Form 10-K (filed 2018-02-21) ↗ |
| Q1 2016 | Apr 3, 2016 | 3,195 | – | Form 10-K (filed 2018-02-21) ↗ |
Breakdown
What makes up consumer health segment total [spun off as kenvue in fy2023q3] — worldwide sales ($m)
- Consumer Health Segment Total [spun off as Kenvue in FY2023Q3] — U.S. sales ($M)1,787 · Q2 2023
- Consumer Health Segment Total [spun off as Kenvue in FY2023Q3] — International sales ($M)2,224 · Q2 2023
- Consumer Health Segment Total [spun off as Kenvue in FY2023Q3] — Worldwide reported growth YoY (%)5.4% · Q2 2023
- Consumer Health Segment Total [spun off as Kenvue in FY2023Q3] — Worldwide operational (constant-currency) growth YoY (%)7.7% · Q2 2023
- Consumer Health — Worldwide adjusted operational growth ex-A&D YoY (%)7.7% · Q2 2023
- Over-the-Counter (OTC) Medicines (TYLENOL, MOTRIN, ZYRTEC) — Worldwide sales ($M)1,659 · Q2 2023
- Skin Health / Beauty (NEUTROGENA, AVEENO) — Worldwide sales ($M)1,148 · Q2 2023
- Oral Care (LISTERINE) — Worldwide sales ($M)398 · Q2 2023
- Baby Care (JOHNSON'S) — Worldwide sales ($M)360 · Q2 2023
- Women's Health — Worldwide sales ($M)238 · Q2 2023
- Wound Care / Other (BAND-AID) — Worldwide sales ($M)207 · Q2 2023
Cite this data
StockData. (2026). Johnson & Johnson Consumer Health Segment Total [spun off as Kenvue in FY2023Q3] — Worldwide sales ($M) ($M), quarterly Q1 2016–Q2 2023 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/seg_consumer_legacy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.